Why is Alivus Life falling/rising?

As of 06-Aug, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at Rs 956.40, which reflects a decrease of Rs 31.0 or 3.14%. Today's price summary indicates that the stock has underperformed its sector by 1.08%, touching an intraday low of Rs 936, which represents a drop of 5.21%. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Over the past week, the stock has decreased by 8.68%, while it has also seen a decline of 7.68% over the past month. Although the company has shown consistent returns over the last three years, with a 3.32% return in the last year, its long-term growth prospects appear limited due to modest net sales and operating profit growth rates of 4.49% and 2.26%, respectively, over the last five years.
In the broader market context, the Sensex has declined by only 1.15% over the past week and 3.46% over the past month, indicating that Alivus Life's performance is significantly worse than the benchmark. The Pharmaceuticals & Drugs sector has also fallen by 2.06%, contributing to the stock's downward movement. Despite a rise in investor participation, with delivery volume increasing by 116.81% against the 5-day average, the overall sentiment remains negative due to the stock trading at a premium compared to its peers and the flat results reported in June. The company's high management efficiency and low debt levels are positive factors, but they are overshadowed by concerns regarding its growth potential and recent performance.